
Opinion|Videos|December 8, 2023
Navigating Endocrine Resistance in the Treatment of ER+/HER2- Metastatic Breast Cancer
Author(s)Hope S. Rugo, MD
Current treatment landscape in ER+/HER2- metastatic breast cancer and unmet needs in overcoming treatment resistance.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Early Relapse Guides Use of CAR T vs Other Options in LBCL
4
FDA Fast-Tracks Muzastotug Combo in MSS Metastatic Colorectal Cancer
5











































